Atea Pharmaceuticals Inc. (AVIR) is advancing late-stage antiviral programs, led by its Phase 3 hepatitis C trials of Bemnifosbuvir and Ruzasvir. With enrollment completed in the pivotal C-BEYOND study and topline results expected in 2026, the company is positioning itself to deliver shorter, more tolerable treatment options.
Backed by a solid cash position and a growing pipeline that now includes hepatitis E candidates, Atea continues to attract market attention ahead of critical trial data.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.